CM
UBX

Caption Management’s Unity Biotechnology UBX Stock Holding History

Caption Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-22,500
Closed -$127K – 1854
2022
Q2 		$127K Hold
22,500
– – ﹤0.01% 1279
2022
Q1 		$252K Buy
+22,500
New +$252K ﹤0.01% 1243

Other funds holding UBX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
ACM
Altium Capital Management New York $42M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Caption Management's UBX Position: Q3 2022 in Review

Caption Management sold out of Unity Biotechnology (UBX) in Q3 2022, closing a stake of 22,500 shares — an estimated $127K sold.

Caption Management first reported a position in UBX in Q1 2022 and held it in 2 quarters. The position peaked at $252K in Q1 2022. 72 funds tracked by Wall St. Rank hold UBX as of Q3 2022.

  • Caption Management reported no remaining Unity Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Caption Management sold 22,500 Unity Biotechnology shares in Q3 2022, an estimated $127K.
  • Caption Management first reported a position in Unity Biotechnology in Q1 2022 and held it in 2 quarters.
  • Caption Management's Unity Biotechnology position peaked at $252K in Q1 2022.
  • 72 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2022.

Based on Caption Management's 13F filing for Q3 2022, filed 14 Nov 2022.